SCM
IONS icon

Stonebridge Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Stonebridge Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-7,425
Closed -$256K – 185
2014
Q2 		$256K Buy
+7,425
New +$234K 0.1% 156

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stonebridge Capital Management's IONS Position: Q3 2014 in Review

Stonebridge Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2014, closing a stake of 7,425 shares — an estimated $256K sold.

Stonebridge Capital Management first reported a position in IONS in Q2 2014 and held it in 1 quarter. The position peaked at $256K in Q2 2014. 240 funds tracked by Wall St. Rank hold IONS as of Q3 2014.

  • Stonebridge Capital Management reported no remaining Ionis Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Stonebridge Capital Management sold 7,425 Ionis Pharmaceuticals shares in Q3 2014, an estimated $256K.
  • Stonebridge Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Stonebridge Capital Management's Ionis Pharmaceuticals position peaked at $256K in Q2 2014.
  • 240 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2014.

Based on Stonebridge Capital Management's 13F filing for Q3 2014, filed 30 Oct 2014.